Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
Immuneering Corporation (Nasdaq: IMRX) announced its participation at the William Blair Biotech Focus Conference 2022 on July 13, 2022. CEO Ben Zeskind will be part of a panel discussing pre-clinical data related to the company’s lead product candidate, IMM-1-104, which targets pan-KRAS/NRAS activity in advanced solid tumors. Immuneering’s innovative approach combines translational bioinformatics with unique drug design strategies to enhance treatment outcomes for cancer patients, leveraging its proprietary 3D tumor modeling and bioinformatics platforms.
- Participation in William Blair Biotech Focus Conference may enhance visibility and investor interest.
- Discussion of IMM-1-104 could attract attention to its potential as a treatment for advanced solid tumors.
- Forward-looking statements indicate inherent uncertainties and risks in drug development.
- No new clinical trial data or financial metrics were provided, leaving uncertainty about future progress.
CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in William Blair Biotech Focus Conference 2022. Participating in a panel discussion will be Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering. The discussion will include an overview of the pre-clinical data highlighting the pan-KRAS/NRAS activity of IMM-1-104.
Topic: Next Generation Small Molecules in Oncology
Format: Panel discussion
Date: July 13, 2022
Time: 12:00 – 12:30 pm ET
About Immuneering Corporation
Immuneering aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Immuneering has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneering’s disease-agnostic discovery platform enables the company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Immuneering’s lead product candidate IMM-1-104 aims to achieve pan-KRAS/NRAS activity that selectively impacts cancer cells to a greater extent than healthy cells. It is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway by driving deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to spare healthy cells. IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations, and is translationally guided by Immuneering’s proprietary, human-aligned 3D tumor modeling platform combined with patient-aligned bioinformatics. In addition to IMM-1-104, Immuneering is evaluating its MEK-io product candidate, IMM-6-415, in IND-enabling studies, and has five other oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway, as well as two discovery stage neuroscience programs.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering’s expectations regarding the sufficiency of Immuneering’s cash, cash equivalents and marketable securities, its full year GAAP operating expenses for 2022, the treatment potential of IMM-1-104 and IMM-6-415, the timing of submission of the IND and commencement of clinical trials for IMM-1-104 and IMM-6-415, the target indications of Immuneering’s planned Phase 1/2a trial, and Immuneering’s ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering’s most recent Form 10-Q filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.
Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation
617-500-8080
rkusko@immuneering.com
Investor Contact:
Susan A. Noonan
S.A. Noonan Communications
917-513-5303
susan@sanoonan.com
FAQ
What is Immuneering's stock symbol?
When is Immuneering participating in the William Blair Biotech Focus Conference?
Who is speaking on behalf of Immuneering at the conference?
What drug candidate will be discussed at the conference?
What are the potential applications of IMM-1-104?
